YOU ARE NOW LEAVING IDERACLINICALTRIALS.COM
In the Illuminate clinical trials, researchers are evaluating an investigational drug called tilsotolimod (IMO-2125) to help treat patients with metastatic melanoma and other types of cancer.
Tilsotolimod is an investigational drug. That means it has not been approved for use by any regulatory agency, such as the US Food and Drug Administration (FDA).
For adults who have solid tumors, including melanoma, that have not responded to available approved treatments.
For adults who have metastatic melanoma that has not responded to available approved treatments.
For adults who have metastatic melanoma that has not responded to available treatments.